{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:40:34Z","timestamp":1794584434753,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"GHD-Pink program"},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013816","name":"Departament d'Empresa i Coneixement, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021 SGR 1510"],"award-info":[{"award-number":["2021 SGR 1510"]}],"id":[{"id":"10.13039\/501100013816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013816","name":"Departament d'Empresa i Coneixement, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021 SGR 01112"],"award-info":[{"award-number":["2021 SGR 01112"]}],"id":[{"id":"10.13039\/501100013816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00892"],"award-info":[{"award-number":["PI20\/00892"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CPII19\/00033"],"award-info":[{"award-number":["CPII19\/00033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01303"],"award-info":[{"award-number":["PI19\/01303"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01200"],"award-info":[{"award-number":["PI22\/01200"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES20095LLOP"],"award-info":[{"award-number":["INVES20095LLOP"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["POSTD211413AREN"],"award-info":[{"award-number":["POSTD211413AREN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PERIS - Departament de Salut, Generalitat de Catalunya","award":["SLT017\/20\/000081"],"award-info":[{"award-number":["SLT017\/20\/000081"]}],"id":[{"id":"https:\/\/ror.org\/01bg62x04","id-type":"ROR","asserted-by":"crossref"}]},{"name":"La Caixa Foundation","award":["LCF\/BQ\/DI19\/11730051 (ID 100010434"],"award-info":[{"award-number":["LCF\/BQ\/DI19\/11730051 (ID 100010434"]}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["AGAUR 2020 FI-B 00584"],"award-info":[{"award-number":["AGAUR 2020 FI-B 00584"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010552","name":"Departament de Salut, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["PERIS SLT028\/23\/000310"],"award-info":[{"award-number":["PERIS SLT028\/23\/000310"]}],"id":[{"id":"10.13039\/501100010552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PRE2021-099087"],"award-info":[{"award-number":["PRE2021-099087"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-024-01370-z","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T11:02:34Z","timestamp":1724670154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models"],"prefix":"10.1186","volume":"16","author":[{"given":"Andrea","family":"Herencia-Ropero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Llop-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Staniszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Dom\u00e8nech-Viv\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Garc\u00eda-Galea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Moles-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heura","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique J.","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Verdaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Calero-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Tobalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nuciforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orland","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Guti\u00e9rrez-Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep V.","family":"Forment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Albertella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-1065","authenticated-orcid":false,"given":"Violeta","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"8","key":"1370_CR1","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1370_CR2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1370_CR3","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"10106","key":"1370_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u201361.","journal-title":"Lancet"},{"issue":"26","key":"1370_CR5","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"25","key":"1370_CR6","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"25","key":"1370_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"6","key":"1370_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"1370_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u201363.","journal-title":"N Engl J Med"},{"issue":"25","key":"1370_CR10","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"4","key":"1370_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"22","key":"1370_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"32","key":"1370_CR13","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38(32):3763\u201372.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1370_CR14","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa2200043.","journal-title":"NEJM Evid"},{"issue":"7035","key":"1370_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.","journal-title":"Nature"},{"issue":"7035","key":"1370_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"6330","key":"1370_CR17","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"issue":"362","key":"1370_CR18","doi-asserted-by":"publisher","first-page":"362ps317","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier Y, O\u2019Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps317.","journal-title":"Sci Transl Med."},{"issue":"1","key":"1370_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-018-0612-8","volume":"10","author":"P Francica","year":"2018","unstructured":"Francica P, Rottenberg S. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. Genome Med. 2018;10(1):101.","journal-title":"Genome Med"},{"issue":"4","key":"1370_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O'Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547\u201360.","journal-title":"Mol Cell"},{"issue":"20","key":"1370_CR21","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","volume":"28","author":"V Serra","year":"2022","unstructured":"Serra V, Wang AT, Castroviejo-Bermejo M, et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. Clin Cancer Res. 2022;28(20):4536\u201350.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1370_CR22","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington SL, Shah PD, Martin L, et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin Cancer Res. 2023;29(15):2800\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1370_CR23","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15\u201328.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1370_CR24","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"issue":"1","key":"1370_CR25","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","volume":"9","author":"GE Ronson","year":"2018","unstructured":"Ronson GE, Piberger AL, Higgs MR, et al. PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. Nat Commun. 2018;9(1):746.","journal-title":"Nat Commun"},{"issue":"1","key":"1370_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","volume":"122","author":"J Farres","year":"2013","unstructured":"Farres J, Martin-Caballero J, Martinez C, et al. Parp-2 is required to maintain hematopoiesis following sublethal gamma-irradiation in mice. Blood. 2013;122(1):44\u201354.","journal-title":"Blood"},{"issue":"7","key":"1370_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/cdd.2014.202","volume":"22","author":"J Farres","year":"2015","unstructured":"Farres J, Llacuna L, Martin-Caballero J, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 2015;22(7):1144\u201357.","journal-title":"Cell Death Differ"},{"issue":"19","key":"1370_CR28","doi-asserted-by":"publisher","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","volume":"64","author":"JW Johannes","year":"2021","unstructured":"Johannes JW, Balazs A, Barratt D, et al. Discovery of 5-4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl-N-methylpyridine-2-carboxamide (AZD5305): a PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs. J Med Chem. 2021;64(19):14498\u2013512.","journal-title":"J Med Chem"},{"issue":"21","key":"1370_CR29","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","volume":"28","author":"G Illuzzi","year":"2022","unstructured":"Illuzzi G, Staniszewska AD, Gill SJ, et al. Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin Cancer Res. 2022;28(21):4724\u201336.","journal-title":"Clin Cancer Res"},{"key":"1370_CR30","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.12688\/f1000research.10082.1","volume":"5","author":"MJ Ahdesmaki","year":"2016","unstructured":"Ahdesmaki MJ, Gray SR, Johnson JH, Lai Z. Disambiguate: an open-source application for disambiguating two species in next generation sequencing data from grafted samples. F1000Res. 2016;5:2741.","journal-title":"F1000Res"},{"issue":"11","key":"1370_CR31","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai Z, Markovets A, Ahdesmaki M, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44(11):e108.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1370_CR32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12859-023-05407-9","volume":"24","author":"K Janssen","year":"2023","unstructured":"Janssen K, Duran-Romana R, Bottu G, et al. SNPeffect 5.0: large-scale structural phenotyping of protein coding variants extracted from next-generation sequencing data using AlphaFold models. BMC Bioinformatics. 2023;24(1):287.","journal-title":"BMC Bioinformatics."},{"issue":"4","key":"1370_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"issue":"12","key":"1370_CR34","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"6","key":"1370_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101\u20138.","journal-title":"Nat Protoc"},{"issue":"5","key":"1370_CR36","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/humu.23411","volume":"39","author":"M Colombo","year":"2018","unstructured":"Colombo M, Lopez-Perolio I, Meeks HD, et al. The BRCA2 c.68\u20137T > A variant is not pathogenic: a model for clinical calibration of spliceogenicity. Hum Mutat. 2018;39(5):729\u201341.","journal-title":"Hum Mutat"},{"issue":"12","key":"1370_CR37","doi-asserted-by":"publisher","first-page":"e9172","DOI":"10.15252\/emmm.201809172","volume":"10","author":"M Castroviejo-Bermejo","year":"2018","unstructured":"Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018;10(12):e9172.","journal-title":"EMBO Mol Med"},{"issue":"30","key":"1370_CR38","doi-asserted-by":"publisher","first-page":"E2848","DOI":"10.1073\/pnas.1310677110","volume":"110","author":"A Ballabeni","year":"2013","unstructured":"Ballabeni A, Zamponi R, Moore JK, Helin K, Kirschner MW. Geminin deploys multiple mechanisms to regulate Cdt1 before cell division thus ensuring the proper execution of DNA replication. Proc Natl Acad Sci U S A. 2013;110(30):E2848\u20132853.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1370_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57(1):289\u2013300.","journal-title":"J R Statist Soc B"},{"issue":"1","key":"1370_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1\u201348.","journal-title":"J Stat Softw"},{"key":"1370_CR41","unstructured":"Therneau T. coxme: mixed effects Cox models. R package version 2.2\u201318.1. 2022. https:\/\/cran.r-project.org\/web\/packages\/coxme\/coxme.pdf."},{"key":"1370_CR42","unstructured":"Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing. 2023.\u00a0https:\/\/www.R-project.org\/."},{"issue":"8","key":"1370_CR43","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","volume":"20","author":"H Dev","year":"2018","unstructured":"Dev H, Chiang TW, Lescale C, et al. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat Cell Biol. 2018;20(8):954\u201365.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"1370_CR44","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/1535-7163.MCT-17-0256","volume":"19","author":"PH Park","year":"2020","unstructured":"Park PH, Yamamoto TM, Li H, et al. Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations. Mol Cancer Ther. 2020;19(2):602\u201313.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1370_CR45","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","volume":"29","author":"C Cruz","year":"2018","unstructured":"Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018;29(5):1203\u201310.","journal-title":"Ann Oncol"},{"issue":"8","key":"1370_CR46","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/0008-5472.CAN-21-2409","volume":"82","author":"B Pellegrino","year":"2022","unstructured":"Pellegrino B, Herencia-Ropero A, Llop-Guevara A, et al. Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification. Cancer Res. 2022;82(8):1646\u201357.","journal-title":"Cancer Res"},{"issue":"9","key":"1370_CR47","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","volume":"76","author":"Y Wang","year":"2016","unstructured":"Wang Y, Bernhardy AJ, Cruz C, et al. The BRCA1-Delta11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Res. 2016;76(9):2778\u201390.","journal-title":"Cancer Res"},{"issue":"10","key":"1370_CR48","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","volume":"10","author":"SJ Pettitt","year":"2020","unstructured":"Pettitt SJ, Frankum JR, Punta M, et al. Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 2020;10(10):1475\u201388.","journal-title":"Cancer Discov"},{"issue":"1","key":"1370_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","volume":"32","author":"L Tobalina","year":"2021","unstructured":"Tobalina L, Armenia J, Irving E, O\u2019Connor MJ, Forment JV. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann Oncol. 2021;32(1):103\u201312.","journal-title":"Ann Oncol"},{"issue":"2","key":"1370_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting SF, Callen E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243\u201354.","journal-title":"Cell"},{"issue":"18","key":"1370_CR51","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/0008-5472.CAN-14-0306","volume":"74","author":"JG Glanzer","year":"2014","unstructured":"Glanzer JG, Liu S, Wang L, Mosel A, Peng A, Oakley GG. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014;74(18):5165\u201372.","journal-title":"Cancer Res"},{"issue":"7668","key":"1370_CR52","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548(7668):466\u201370.","journal-title":"Nature"},{"issue":"44","key":"1370_CR53","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1370_CR54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/2767-9764.CRC-22-0423","volume":"3","author":"G Dellavedova","year":"2023","unstructured":"Dellavedova G, Decio A, Formenti L, et al. The PARP1 inhibitor AZD5305 impairs ovarian adenocarcinoma progression and visceral metastases in patient-derived xenografts alone and in combination with carboplatin. Cancer Res Commun. 2023;3(3):489\u2013500.","journal-title":"Cancer Res Commun"},{"issue":"8","key":"1370_CR55","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/annonc\/mdu187","volume":"25","author":"J Balmana","year":"2014","unstructured":"Balmana J, Tung NM, Isakoff SJ, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014;25(8):1656\u201363.","journal-title":"Ann Oncol"},{"issue":"10","key":"1370_CR56","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Dieras","year":"2020","unstructured":"Dieras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(10):1269\u201382.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1370_CR57","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497\u2013509.","journal-title":"Lancet Oncol"},{"key":"1370_CR58","doi-asserted-by":"publisher","unstructured":"Abraham JE, Pinilla K, Dayimu A, et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. 2024. https:\/\/doi.org\/10.1038\/s41586-024-07384-2.","DOI":"10.1038\/s41586-024-07384-2"},{"issue":"9","key":"1370_CR59","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437\u201347.","journal-title":"Ann Oncol"},{"issue":"1","key":"1370_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/path.5055","volume":"245","author":"JEA Lee","year":"2018","unstructured":"Lee JEA, Li N, Rowley SM, et al. Molecular analysis of PALB2-associated breast cancers. J Pathol. 2018;245(1):53\u201360.","journal-title":"J Pathol"},{"key":"1370_CR61","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-019-0115-9","volume":"5","author":"A Li","year":"2019","unstructured":"Li A, Geyer FC, Blecua P, et al. Homologous recombination DNA repair defects in PALB2-associated breast cancers. NPJ Breast Cancer. 2019;5:23.","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"1370_CR62","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41588-021-00949-1","volume":"53","author":"P Srinivasan","year":"2021","unstructured":"Srinivasan P, Bandlamudi C, Jonsson P, et al. The context-specific role of germline pathogenicity in tumorigenesis. Nat Genet. 2021;53(11):1577\u201385.","journal-title":"Nat Genet"},{"key":"1370_CR63","volume-title":"PETRA: a first-in-class, first-in-human trial of the next-generation PARP1-selective inhibitor AZD5305 in patients with BRCA1\/2, PALB2 or RAD51C\/D mutations","author":"TA Yap","year":"2022","unstructured":"Yap TA, Im S-A, Schram AM, et al. PETRA: a first-in-class, first-in-human trial of the next-generation PARP1-selective inhibitor AZD5305 in patients with BRCA1\/2, PALB2 or RAD51C\/D mutations. New Orleans, USA: In. AACR annual meeting; 2022."},{"issue":"1","key":"1370_CR64","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41523-021-00283-z","volume":"7","author":"EE Parkes","year":"2021","unstructured":"Parkes EE, Humphries MP, Gilmore E, et al. The clinical and molecular significance associated with STING signaling in breast cancer. NPJ Breast Cancer. 2021;7(1):81.","journal-title":"NPJ Breast Cancer"},{"key":"1370_CR65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5559","volume-title":"BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer","author":"N Lukashchuk","year":"2022","unstructured":"Lukashchuk N, Armenia J, Luis Tobalina T, et al. BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer. Chicago, USA: In. ASCO annual meeting; 2022."},{"issue":"4","key":"1370_CR66","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","volume":"35","author":"E Harvey-Jones","year":"2024","unstructured":"Harvey-Jones E, Raghunandan M, Robbez-Masson L, et al. Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer. Ann Oncol. 2024;35(4):364\u201380.","journal-title":"Ann Oncol"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-024-01370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-024-01370-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-024-01370-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T12:05:21Z","timestamp":1724673921000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-024-01370-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1186\/s13073-024-01370-z","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fresh tumor samples from cancer patients were collected for implantation into nude mice under a protocol approved by the Ethics Committee for Clinical Research (PR(AG)484\/2017) and an associated written informed consent. Procedures involving human specimens were conducted according to the principles of the Helsinki Declaration. Experiments were conducted following the European Union\u2019s animal care directive (2010\/63\/EU) and were approved by the Ethical Committee of Animal Experimentation of the Vall d\u2019Hebron Research Institute. All patients provided written informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ALG, VS, and JB are co-inventors of a patent related to this work (WO2019122411A1). We report research grants from AstraZeneca (VS) and personal fees and\/or nonfinancial support from AstraZeneca (JB, VS), Pfizer (JB), and GSK (VS). ADS, FJCN, ST, LT, EL, AL, ALG, JF, MJOC, and MA are full time-time employees and shareholders at AZ. The remaining authors declare that they have no competing interests. The PARPi and ATRi used in this study were provided by AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}